Search peptides, terms, sources/
Melanocortin

Melanotan II

Also known as: MT-II · MT2 · Melanotan-2

Synthetic melanocortin receptor agonist studied for skin tanning. Not licensed in the UK; human evidence is a three-volunteer pilot plus case reports.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Melanotan II is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials1 human trial · 1 human observational

What is Melanotan II?

Melanotan II is a synthetic peptide that activates several melanocortin receptors, studied for skin tanning. It is not licensed in the UK, and the human evidence is a three-volunteer pilot study plus case reports associating use with changes in moles and melanoma, which cannot show cause.

It acts on several melanocortin receptors without selectivity. Its earliest human study was a three-volunteer pilot. The separate, more selective molecule PT-141 (bremelanotide) was later developed from the same research.

Class
Synthetic cyclic melanocortin-receptor agonist (non-selective)
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Melanotan II work?

Melanotan II activates several melanocortin receptors. Activity at MC1R makes skin cells produce more pigment, which causes tanning. Activity at MC4R in the brain affects sexual function and appetite pathways. Because it is not selective, it also affects moles and other pigmented skin spots.

The mechanism in more detail

Melanotan II acts as a non-selective agonist across melanocortin receptors, meaning it activates more than one receptor subtype in this family rather than targeting a single one. Its tanning effect is attributed to activity at MC1R, the receptor that regulates melanin production in skin melanocytes. Its effects on erectile function and sexual desire are attributed to activity at MC4R, a receptor also implicated in appetite and other central nervous system pathways.

These sexual-function effects were not the compound’s original research target. Melanotan II was developed as a photoprotection and tanning agent; its erectile and libido effects emerged as an incidental observation during its foundational 1996 human dosing study, in which spontaneous erections were recorded alongside dose-dependent tanning. That observation subsequently motivated the development of PT-141 (bremelanotide), a related but MC4R-selective compound, as a distinct research programme.

Because Melanotan II acts non-selectively on melanocortin pathways involved in pigmentation, its use has been studied and reported in connection with changes to pigmented skin lesions. This safety-relevant evidence, along with the peptide’s UK regulatory status, is set out separately in the Safety Findings and Regulatory Status sections of this page.

Mechanisms and targets

Melanocortin receptor agonism (non-selective)Melanogenesis / melanocyte stimulation (MC1R)Sexual function / libido pathway (MC4R)MC1R (melanocortin 1 receptor)MC4R (melanocortin 4 receptor)

Classification and structure

Names
Melanotan II; MT-II; MT2; Melanotan-2
Class
Synthetic cyclic melanocortin-receptor agonist (non-selective)
Origin
Fully synthetic
Routes used in the research
Subcutaneous injection in the foundational Phase I study. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Melanotan II has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
11000

Three-volunteer Phase I study Preliminary

In a single-blind, alternating-day, placebo-controlled pilot Phase I study in 3 healthy male volunteers (subcutaneous MT-II, with the dose raised step by step over 2 weeks), the study confirmed dose-dependent skin tanning and documented dose-limiting nausea, flushing and spontaneous penile erections as the primary adverse or incidental effects.

Study type
Human trial
Population
Human, healthy male volunteers, n=3
Source
1 Dorr et al., 1996

Limitation: Extremely small sample (n=3), single-centre, pilot-stage design, not replicated at scale in a larger controlled trial since.

Limitations in full

Extremely small sample (n=3), single-centre, pilot-stage design, not replicated at scale in a larger controlled trial since. This is the foundational human dosing study for the compound and should be presented as historically important but far too small to support any strength-of-evidence claim beyond Preliminary.

Naevi and melanoma case reports Limited

Case reports and a case series in the dermatology literature associate Melanotan II use with the development of new dysplastic naevi, eruptive melanocytic naevi and malignant melanoma (including a mucosal melanoma case following nasal-spray use), and with rapid changes in existing pigmented lesions that can make skin-cancer detection more difficult.

Study type
Human observational
Population
Human case reports and small case series (individual reports, not a cohort study)
Source
2 Paurobally et al., 2011

Limitation: Case reports document association, not causation, and cannot establish incidence or relative risk.

Limitations in full

Case reports document association, not causation, and cannot establish incidence or relative risk. Multiple independent case reports from different research groups (Belgium 2011; UK oral and maxillofacial surgery group 2025) strengthen the signal beyond a single isolated report, which is why this sits at Limited rather than Preliminary, but it remains short of any controlled epidemiological study.

What safety findings have been reported?

2 safety findings are recorded for Melanotan II. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Pigmented-lesion changes reported

Published case reports describe melanoma (including mucosal melanoma following nasal-spray use), dysplastic naevus eruption and other pigmented-lesion changes temporally associated with Melanotan II use.

Source
2 Paurobally et al., 2011

MHRA Yellow Card reports

Between 1 January 2011 and 9 December 2021, the MHRA received 13 suspected Adverse Drug Reaction reports associated with Melanotan II via the Yellow Card scheme (yearly breakdown: 2011: 3, 2012: 2, 2013: 1, 2014: 3, 2015 to 2017: 0, 2018: 2, 2019: 2, 2020 to 2021: 0). The MHRA's own covering letter states that Yellow Card inclusion does not establish causation, that reporting is voluntary and subject to significant under-reporting, and that the 13-report figure should not be read as the true incidence of adverse reactions.

Source
3 MHRA, 2021

What is Melanotan II's UK regulatory status?

Marketing authorisation
No product containing Melanotan II holds a UK marketing authorisation. No Melanotan product has ever been authorised for use in the UK.
Prescription status
Not applicable, no licensed UK product was found to classify as POM. Where a product is determined to be a medicinal product under the Human Medicines Regulations 2012 and is not appropriately authorised, its sale, supply and advertising is unlawful regardless of POM, P or GSL classification.
Medicine class
Not a licensed medicine. Whether an individual product is a medicine at all is determined case-by-case (see MHRA medicinal-product status).
MHRA position
Per the MHRA's own 20 December 2021 FOI response, the MHRA determines on a case-by-case basis whether a Melanotan II product is a medicinal product under the Human Medicines Regulations 2012, considering factors including effect on the body and manner of use. The MHRA's own letter states the definition of a medicine does not allow it to consider mode of administration in isolation, so injectable tanning products containing Melanotan II are not automatically medicines, and nasal tanning sprays containing Melanotan II will not generally be regulated as medicinal products where no medicinal claims are made. The MHRA states it has repeatedly taken action to remove Melanotan products so identified from sale for over 10 years and will continue to do so where products are determined to be medicinal products.
Authorised use
None.
Research use
No distinct research-use carve-out identified in MHRA guidance for Melanotan II specifically; Melanotan products are typically marketed directly as tanning and cosmetic products rather than research chemicals.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Melanotan II is recorded as not licensed in the UK (checked 14 August 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life SciencesHuman clinical trial · PMID 8637402 · Original ↗
  2. Paurobally D, Jason F, Dezfoulian B, Nikkels AF (2011). Melanotan-associated melanoma. British Journal of DermatologyCase report / case series · DOI 10.1111/j.1365-2133.2011.10273.x · Original ↗
  3. MHRA Vigilance and Risk Management of Medicines Division / FOI Team (2021). Freedom of Information response FOI 21/1237, Yellow Card reports for Melanotan II products (2011-2021) and regulatory classification. Medicines and Healthcare products Regulatory Agency (MHRA), gov.uk · Original ↗

Questions about Melanotan II

What is Melanotan II?

Melanotan II is a synthetic peptide that activates several melanocortin receptors, studied for skin tanning. It is not licensed in the UK, and the human evidence is a three-volunteer pilot study plus case reports associating use with changes in moles and melanoma, which cannot show cause. Read what it is.

Is Melanotan II licensed in the UK?

PeptGuru records Melanotan II's UK status as: Not licensed in the UK. No product containing Melanotan II holds a UK marketing authorisation. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Melanotan II show?

PeptGuru records 2 research findings for Melanotan II: 1 from a human trial and 1 from a human observational study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Melanotan II?

2 safety findings are recorded, including: pigmented-lesion changes reported; MHRA yellow card reports. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Melanotan II?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team

How findings are graded: the grading method. All changes.

  • Afamelanotide

    Synthetic alpha-MSH analogue studied in erythropoietic protoporphyria (EPP). Licensed in the UK for adults with EPP; not recommended for routine NHS use. Not the same as Melanotan II.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • PT-141 (Bremelanotide)Bremelanotide

    No UK marketing authorisation found; authorised in the US. Selective melanocortin-4 receptor agonist studied for low sexual desire in women.

    MelanocortinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Setmelanotide

    Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

Compare Melanotan II with Afamelanotide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.